✦ LIBER ✦

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

✍ Scribed by Dharminder Chauhan; Laurence Catley; Guilan Li; Klaus Podar; Teru Hideshima; Mugdha Velankar; Constantine Mitsiades; Nicolas Mitsiades; Hiroshi Yasui; Anthony Letai; Huib Ovaa; Celia Berkers; Benjamin Nicholson; Ta-Hsiang Chao; Saskia T.C. Neuteboom; Paul Richardson; Michael A. Palladino; Kenneth C. Anderson

Book ID: 113523619
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 873 KB
Volume: 8
Category: Article
ISSN: 1535-6108
DOI: 10.1016/j.ccr.2005.10.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The novel, orally bioavailable HSP90 inh

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

✍ Britta Lamottke; Martin Kaiser; Maren Mieth; Ulrike Heider; Zhenhai Gao; Zariana 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB

A novel NF-κB inhibitor DHMEQ selectivel

A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo

✍ Mariko Watanabe; Md. Zahidunnabi Dewan; Takamitu Okamura; Masataka Sasaki; Kinji 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 453 KB

Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i